Drugs / TSRA-196
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07227207 | Apr 2026 → Mar 2029 expected | alpha 1-antitrypsin deficiency | Tessera Therapeutics, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-01 | Regeneron Pharmaceuticals | Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) regeneron.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSRA-196 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07227207 ↗ |
| Route | Intravenous | “via intravenous (IV) infusion” NCT07227207 ↗ |